STATEMENT UNDER 37 CFR 3.73(b)

Арр	licant/	Patent Ow	owner: Sekhar Boddupalli et al.		
Application No./Patent No.: 10/714,152			tent No.: 10/714,152 Filed/Issue Date	November 13, 2003	
Titled: CHROMAN DERIVATIVES FOR THE REDUCTION OF INFLAMMATION SYMPTOMS					
Monsanto Technology LLC a corporation					
(Name of Assignee) (Type o			(Type of Assignee, e.g., corporati	ion, partnership, university, government agency, etc.	
states that it is:					
1.	X	the assig	the assignee of the entire right, title, and interest in;		
2.		an assign (The exte	an assignee of less than the entire right, title, and interest in (The extent (by percentage) of its ownership interest is		
3.		the assignee of an undivided interest in the entirety of (a complete assignment from one of the joint inventors was made)			
the patent application/patent identified above, by virtue of either:					
A.		An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, reame, or for which a copy therefore is attached.			
OR					
В.	A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows: 1. From: Sekhar Boddupalli, Guy Miller, Bing Wang To: Galileo Pharmaceuticals, Inc.				
			The document was recorded in the United States Patent and Trader Reel 014244 , Frame 0436 , or		
		2. From:	m: Galileo Pharmaceuticals, Inc. To: Monsa	anto Technology LLC	
			The document was recorded in the United States Patent and Trader Reel 023276 Frame 0483 or		
		3. From:			
			The document was recorded in the United States Patent and Trader		
		A al alista	Reel, Frame, or		
Additional documents in the chain of title are listed on a supplemental sheet(s).					
As required by 37 CFR 3.73(b)(1)(i), the documentary evidence of the chain of title from the original owner to the assignee was or concurrently is being, submitted for recordation pursuant to 37 CFR 3.11.					
[NOTE: A separate copy (i.e., a true copy of the original assignment document(s)) must be submitted to Assignment Division in accordance with 37 CFR Part a to record the assignment in the records of the USPTO. See MPEP 302.08]					
The		signed (who	whose title is supplied below) is authorized to act on behalf of the assig	nee	
Вуго	n V.	Olsen		Assistant General Counsel,	
	Pr	inted or Ty	Typed Name	Title	

This collection of information is required by 3T CFR 3.73(b). The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 3S U.S.C. 122 and 3T CFR 1.11 and 1.14. This collection is delirabled to late 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Then will vary depending upon the individuals case. Any comments on the amount of time you require to complete this form and/or suppetions for reducing this burden, should be sent to the Chief Information Cificer, U.S. Peters of Trademark Officer, U.S. Peters of T

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether disclosure of these records is required by the Freedom of Information Act.
- A record from this system of records may be disclosed, as a routine use, in the course of
 presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to
 opposing counsel in the course of settlement negotiations.
 A record in this system of records may be disclosed, as a routine use, to a Member of
- 3. A "record" in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- 4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, bursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
- 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- 8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspection or an issued patent.
- A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or reculation.